UNSPSC 51132214: Acetaminophen/caffeine/pyrilamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.

The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate.

UNSPSC 51132214 Acetaminophen/caffeine/pyrilamine is a Commodity code that nominally identifies a specific combination pain reliever and stimulant product, but recent state and local procurement activity under this code shows substantial mismatch — the opportunities tagged to it involve naloxone (an opioid antagonist), therapeutic pharmacy initiatives for broad prescription programs, and multi-source generic pharmaceuticals and OTC products rather than the acetaminophen/caffeine/pyrilamine combination itself. State and local health agencies, cooperative purchasing alliances, and county health departments are the primary issuing bodies, though the misalignment between the code name and actual procurement scope suggests this code may be incorrectly applied to pharmaceutical procurement more broadly.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued an IFB (IFB60459723LAS, due July 26, 2026 — noted with a data quality issue as the summary states a due date of July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries to the county's community health building. The Texas Health and Human Services Commission posted a Request for Information (HHS0017013, due April 3, 2026) to explore vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program that would establish direct contracting between state pharmacy benefit programs and pharmaceutical manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802, due March 26, 2026) to establish multiple-award contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with pricing evaluated at 75 percent weight and contract effectiveness set for July 1, 2026. Bidders should verify UNSPSC code accuracy before pursuing opportunities under this classification, as the current tagging does not align with the nominal product scope.